← Back to Search

Nonsteroidal Anti-inflammatory Drug (NSAID)

Aspirin for Stroke (AXIOMATIC-SSP Trial)

Phase 2
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from first dose to up to approximately 38 months

Summary

This trial is testing if adding a new pill to common stroke prevention medications is better at preventing another stroke in patients who have already had one. The new pill works by stopping blood clots from forming.

Eligible Conditions
  • Stroke
  • Mini Stroke

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from first dose to up to approximately 38 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and from first dose to up to approximately 38 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percent of Participants With Model Based Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90
Secondary study objectives
Composite of Percent of Participants With New Ischemic Stroke, MI and All Cause Death
Digit Symbol Substitution Test (DSST)
Modified Rankin Scale (mRS)
+18 more
Other study objectives
Percent of Participants With Ischemic Stroke Events

Trial Design

8Treatment groups
Experimental Treatment
Placebo Group
Group I: Dose 7: BMS-986177 + Aspirin + ClopidogrelExperimental Treatment3 Interventions
Specified Dose on Specified Days
Group II: Dose 6: BMS-986177 + Aspirin + ClopidogrelExperimental Treatment3 Interventions
Specified Dose on Specified Days
Group III: Dose 5: BMS-986177 + Aspirin + ClopidogrelExperimental Treatment3 Interventions
Specified Dose on Specified Days
Group IV: Dose 4: BMS-986177 + Aspirin + ClopidogrelExperimental Treatment3 Interventions
Specified Dose on Specified Days
Group V: Dose 3: BMS-986177 + Aspirin + ClopidogrelExperimental Treatment3 Interventions
Specified Dose on Specified Days
Group VI: Dose 2: BMS-986177 + Aspirin + ClopidogrelExperimental Treatment3 Interventions
Specified Dose on Specified Days
Group VII: Dose 1: BMS-986177 + Aspirin + ClopidogrelExperimental Treatment3 Interventions
Specified Dose on Specified Days
Group VIII: BMS-986177 PlaceboPlacebo Group3 Interventions
Specified Dose on Specified Days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Clopidogrel
2010
Completed Phase 4
~9160
BMS-986177
2016
Completed Phase 2
~2790
Aspirin
2014
Completed Phase 4
~55580

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,682 Previous Clinical Trials
4,122,655 Total Patients Enrolled
9 Trials studying Stroke
20,731 Patients Enrolled for Stroke
Janssen, LPIndustry Sponsor
168 Previous Clinical Trials
308,019 Total Patients Enrolled
3 Trials studying Stroke
17,107 Patients Enrolled for Stroke
~351 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top